|Other Names||Docking protein 1, Downstream of tyrosine kinase 1, p62(dok), pp62, DOK1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7690a was selected from the N-term region of human DOK1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||DOK proteins are enzymatically inert adaptor or scaffolding proteins. They provide a docking platform for the assembly of multimolecular signaling complexes. DOK1 appears to be a negative regulator of the insulin signaling pathway. Modulates integrin activation by competing with talin for the same binding site on ITGB3.|
|Cellular Location||Isoform 1: Cytoplasm. Nucleus.|
|Tissue Location||Expressed in pancreas, heart, leukocyte and spleen. Expressed in both resting and activated peripheral blood T-cells. Expressed in breast cancer|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
DOK1 is constitutively tyrosine phosphorylated in hematopoietic progenitors isolated from chronic myelogenous leukemia (CML) patients in the chronic phase. It may be a critical substrate for p210(bcr/abl), a chimeric protein whose presence is associated with CML. DOK1 contains a putative pleckstrin homology domain at the amino terminus and ten PXXP SH3 recognition motifs. DOK2 binds p120 (RasGAP) from CML cells. It has been postulated to play a role in mitogenic signaling.
Liang, X., et al., J. Biol. Chem. 277(16):13732-13738 (2002).Yamakawa, N., et al., EMBO J. 21(7):1684-1694 (2002).Hubert, P., et al., Eur. J. Immunogenet. 27(3):145-148 (2000).Nemorin, J.G., et al., J. Biol. Chem. 275(19):14590-14597 (2000).Nelms, K., et al., Genomics 53(2):243-245 (1998).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.